Structure Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc (NASDAQ: GPCR) is up a whopping 80% on Monday after reporting “compelling” topline data for its weight-loss drug. $GPCR's weight-loss pill reduces weight by 6.9% The biopharmaceutical firm said its experimental pill helped patients with obesity lose 6.9% of their body weight in about twelve weeks.

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.

Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results

Structure Therapeutics Inc.'s American depositary receipts GPCR, +1.30% gained more than 6% premarket on Monday after the company said its experimental weight-loss pill achieved its aims in a clinical trial.

Structure Therapeutics' stock jumps on weight-loss-pill trial results

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

AST SpaceMobile

Fluence Energy

Sometimes the next big thing stocks to buy and hold are flying well under the radar. Look at Apple (NASDAQ: AAPL ).

Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing

Altimmune

Amgen

AstraZeneca

Merck

Pfizer

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Eli Lilly

Novo Nordisk

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Scholar Rock Holding Corp

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

Sanofi

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

ACM Research

Okeanis Eco Tankers Corp

Evolv Technologies Holdings

SoundHound AI Inc

Urban-gro

Worthington Steel, Inc.

With the major indexes at or near record highs, it's been easy to overlook the performance of the small-cap Russell-2000 Index. While the index is “only” up about 5% in 2024, it's up 21% in the past 12 months, and is slowly starting to catch up to the market rally.

7 Small-Cap Stocks that Wall Street Loves for Good Reason

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company's Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Terns Pharmaceuticals

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Affirm

Apogee Therapeutics Inc

Bristol-Myers

Instacart (Maplebear Inc.)

Confluent

Cargo Therapeutics Inc

Palo Alto Networks

RayzeBio Inc

Snap

Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.

IPO watch 2024: Which new stocks will hit the market?

Structure Therapeutics stock declined sharply due to some data it published. The data show that its flagship drug candidate appears to be safe and effective.

Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now

ALX Onconology Holdings Inc

Avino Silver & Gold Mines

LifeMD 

PetIQ

Skyward Specialty Insurance Group Inc

As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.

7 Small-Cap Stocks That Wall Street Loves for Good Reason

Roche Holding AG

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Structure Therapeutics shares plummeted more than 30% after clinical data for its investigational obesity drug failed to meet expectations.   The company's pill GSBR-1290 is part of a class of weight loss drugs known as glucagon-like peptide 1 (GLP-1) agonists, like Novo Nordisk (NYSE:NVO)'s Wgovy and Ozempic and Eli Lilly and Co (NYSE:LLY)'s Mounjaro and Zepbound.

Structure Therapeutics shares sink after obesity drug trial results disappoint

Structure Therapeutics Inc (NASDAQ: GPCR) says its experimental weight-loss pill showed promising results in a mid-stage trial. Its shares are still down more than 40% at writing.

Structure Therapeutics reports promising results for weight-loss pill

Biotech Structure saw shares dive after the firm disclosed disappointing data for an experimental obesity pill.

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results from a similar treatment from rival Eli Lilly, sending the biotech company's shares tumbling more than 50% on Monday.

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Structure's potential rival to Lilly in weight-loss drugs missed expectations on Monday, and GPCR stock took an absolute beating.

Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader

Structure Therapeutics Inc. American depositary receipts GPCR, +0.97% dropped 40% premarket on Monday after the company released new data from a study of GSBR-1290, its investigational diabetes and obesity treatment. In patients with type 2 diabetes, the drug produced a statistically significant reduction in blood sugar after 12 weeks, Structure said.

Structure Therapeutics stock plunges on new GLP-1 drug data

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

News for Structure Therapeutics Inc Stock (GPCR)